Testing 2 drugs for active lupus skin disease
Part of Immune system & allergy clinical trials.
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a lupus diagnosis with at least moderate skin symptoms (measured by CLASI-A score).
- Your lupus skin disease is active despite using steroid creams or pills or antimalarial drugs for at least 3 months.
- You weigh at least 45 kg and have a BMI between 18 and 30.
- You have a positive test for certain lupus antibodies (ANA or anti-dsDNA).
- You are not pregnant and agree to use two forms of birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
This trial tests an experimental antibody injection (DB-2304) to see if it can improve lupus skin rashes and other lupus symptoms. It is for people with active lupus skin disease who have already tried standard treatments.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This trial tests a new treatment called ACE1831 for people with moderate to severe lupus that has not improved with standard treatments like steroids or other medications. The goal is to see if it can help control lupus activity.
Hear when a new Systemic Lupus Erthematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.